Taittonen M, Räty H, Kirvelä O, Aantaa R, Kanto J
Department of Anaesthesiology, Turku University Hospital, Finland.
Acta Anaesthesiol Scand. 1995 Jul;39(5):628-32. doi: 10.1111/j.1399-6576.1995.tb04139.x.
This pilot study compared the metabolic effects of placebo and 6 mg and 12 mg of oral tizanidine in random double-blind cross-over fashion in five healthy volunteers. The metabolic measurements were made with a portable metabolic chart (Deltatrac, Datex/Instrumentarium, Helsinki, Finland). Heart rate (HR), systolic (BPS), mean (BPM) and diastolic (BPD) blood pressure were measured noninvasively. Subjective assessment of tiredness and dryness of mouth were measured by using visual analogue scales (VAS). There were no statistically significant differences in tiredness or dryness of mouth between the groups. BPD decreased significantly after both doses of tizanidine when compared to placebo (by an average of 12% after 6 mg of tizanidine and 15% after 12 mg of tizanidine from the baseline). Oxygen consumption and energy expenditure decreased significantly after 6 and 12 mg of tizanidine when compared to placebo. The average decrease in oxygen consumption was 3% after 6 mg of tizanidine and 8% after 12 mg of tizanidine, when compared to the baseline. Energy expenditure decreased by an average of 5% after 6 mg of tizanidine and 9% after 12 mg of tizanidine, when compared to the baseline. There were no other statistically significant differences between the groups. This study indicates that 6 and 12 mg of oral tizanidine can be useful for reducing energy expenditure and oxygen consumption without prominent cardiovascular effects.
这项初步研究以随机双盲交叉方式，比较了安慰剂以及6毫克和12毫克口服替扎尼定对5名健康志愿者的代谢影响。代谢测量使用便携式代谢图表（Deltatrac，Datex/Instrumentarium，芬兰赫尔辛基）进行。心率（HR）、收缩压（BPS）、平均压（BPM）和舒张压（BPD）采用无创测量。使用视觉模拟量表（VAS）对疲劳和口干进行主观评估。各组之间在疲劳或口干方面无统计学显著差异。与安慰剂相比，两种剂量的替扎尼定服用后BPD均显著降低（6毫克替扎尼定服用后平均比基线降低12%，12毫克替扎尼定服用后平均比基线降低15%）。与安慰剂相比，6毫克和12毫克替扎尼定服用后耗氧量和能量消耗均显著降低。与基线相比，6毫克替扎尼定服用后耗氧量平均降低3%，12毫克替扎尼定服用后耗氧量平均降低8%。与基线相比，6毫克替扎尼定服用后能量消耗平均降低5%，12毫克替扎尼定服用后能量消耗平均降低9%。各组之间无其他统计学显著差异。这项研究表明，6毫克和12毫克口服替扎尼定可用于降低能量消耗和耗氧量，且无明显心血管影响。
